What decision does your program need to make?

Tell us about the asset, indication, development stage, available data, and the decision your team is working toward. We will assess whether Clyra is a fit and suggest a focused next step.

Define a trial population or biomarker strategy

Interpret response and resistance after early clinical data

Determine which data and evidence can support the decision

Clyra analyses support research and drug-development decisions. Candidate biomarkers require appropriate independent and clinical validation.

DISCUSS A PROGRAM

What decision does your program need to make?

First name

Last name

Work email

Company

Role

Indication

Program stage

Decision type

Available data

Blood-based molecular data

Tissue molecular data

Tissue microenvironment data

Digital pathology

Clinical trial data

Treatment and outcome data

Other

Program question

First name

Last name

Work email

Company

Role

Indication

Program stage

Decision type

Available data

Blood-based molecular data

Tissue molecular data

Tissue microenvironment data

Digital pathology

Clinical trial data

Treatment and outcome data

Other

Program question

A focused first conversation.

Frame the decision

Clarify the asset, indication, development stage, and decision criteria.

Review the evidence

Identify the relevant cohorts, program data, materials, and access constraints.

Define a practical scope

Agree on the analysis, outputs, validation needs, and limitations that matter to the program.

CLYRA BIO

Clyra is building blood-based tumor microenvironment profiling for oncology drug development.

Clyra analyses are intended to support research and drug-development decisions. Candidate biomarkers require appropriate independent and clinical validation.